Mantle Cell Lymphoma
U.S. FDA approves Velcade for injection for aggressive form of non-Hodgkin lymphoma
Published in Cancer Weekly, January 16th, 2007
MCL is a relatively uncommon and aggressive form of non-Hodgkin lymphoma for which there was no standard of care in the relapsed or refractory setting. MCL has a U.S. prevalence of 10,000 patients. Velcade is currently the market leader in multiple myeloma (MM) for patients who have received one prior therapy. This approval marks the first indication for Velcade in lymphoma, the most common blood cancer.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-01-16)
More Articles from Cancer Weekly
- Pancreatic Cancer
M.D. Anderson Cancer Center reports allergy drug slows pancreatic cancer - Cancer Gene Therapy
Data from University of South Alabama, Cancer Institute provide new insights into cancer gene therapy - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at Innsbruck Medical University, Department of Urology - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at Massachusetts General Hospital, Department of Surgery - Cancer Gene Therapy
Data on cancer gene therapy reported by researchers at Institute of Bioengineering and Nanotechnology - Cancer Gene Therapy
Duke University, Department of Biomedical Engineering details research in cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
